H. Roché

716 total citations
24 papers, 551 citations indexed

About

H. Roché is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, H. Roché has authored 24 papers receiving a total of 551 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in H. Roché's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). H. Roché is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (4 papers). H. Roché collaborates with scholars based in France, United States and United Kingdom. H. Roché's co-authors include Bruce Addis, David Layfield, Amit Agrawal, Simona D’Amore, Sun‐Young Kong, Agnieszka Jagiełło-Gruszfeld, Joseph Boni, Laurence Moore, William R. Roche and Mario Campone and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

H. Roché

23 papers receiving 528 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
H. Roché France 12 303 190 183 117 91 24 551
David Mallery United States 4 247 0.8× 212 1.1× 329 1.8× 130 1.1× 87 1.0× 5 498
Amy Krie United States 5 257 0.8× 172 0.9× 268 1.5× 172 1.5× 80 0.9× 10 527
Paul T. Adams United States 10 435 1.4× 115 0.6× 275 1.5× 141 1.2× 63 0.7× 15 611
Angela Sciandivasci Italy 11 425 1.4× 191 1.0× 286 1.6× 100 0.9× 63 0.7× 23 593
Nancy G. Iskander United States 3 218 0.7× 199 1.0× 295 1.6× 116 1.0× 83 0.9× 5 429
Mohamed A. Gouda United States 13 228 0.8× 166 0.9× 219 1.2× 166 1.4× 61 0.7× 58 546
Pam K. Mangat United States 12 468 1.5× 273 1.4× 322 1.8× 140 1.2× 99 1.1× 47 644
Roman Groisberg United States 14 442 1.5× 385 2.0× 167 0.9× 191 1.6× 96 1.1× 50 742
Edna Chow‐Maneval United States 14 458 1.5× 478 2.5× 183 1.0× 231 2.0× 80 0.9× 24 724
Hielke J. Meulenbeld Netherlands 11 283 0.9× 316 1.7× 176 1.0× 149 1.3× 89 1.0× 17 577

Countries citing papers authored by H. Roché

Since Specialization
Citations

This map shows the geographic impact of H. Roché's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. Roché with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. Roché more than expected).

Fields of papers citing papers by H. Roché

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. Roché. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. Roché. The network helps show where H. Roché may publish in the future.

Co-authorship network of co-authors of H. Roché

This figure shows the co-authorship network connecting the top 25 collaborators of H. Roché. A scholar is included among the top collaborators of H. Roché based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. Roché. H. Roché is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Roché, H., et al.. (2023). Osteoma cutis of the scalp on a background of hair loss surgeries. Clinical and Experimental Dermatology. 48(6). 726–728.
2.
Cabarrou, Bastien, Jennifer Wallet, Thomas Brodowicz, et al.. (2018). The importance of jointly analyzing treatment administration and toxicity associated with targeted therapies: a case study of regorafenib in soft tissue sarcoma patients. Annals of Oncology. 29(7). 1588–1593. 5 indexed citations
3.
Cabarrou, Bastien, Jean‐Marie Boher, Emmanuelle Tresch‐Bruneel, et al.. (2016). How to report toxicity associated with targeted therapies?. Annals of Oncology. 27(8). 1633–1638. 10 indexed citations
4.
5.
Shaw, Emily, Andrew M. Hanby, Kevin Wheeler, et al.. (2012). Observer agreement comparing the use of virtual slides with glass slides in the pathology review component of the POSH breast cancer cohort study. Journal of Clinical Pathology. 65(5). 403–408. 26 indexed citations
6.
Roché, H., et al.. (2011). Expression of calretinin by breast carcinoma and the potential for misdiagnosis of mesothelioma. Histopathology. 59(5). 950–956. 24 indexed citations
7.
Layfield, David, et al.. (2010). Intraoperative assessment of sentinel lymph nodes in breast cancer. British journal of surgery. 98(1). 4–17. 84 indexed citations
8.
Cazaux, Christophe, Valérie Bergoglio, Ana Manuel Dantas Machado, et al.. (2010). 132 POLQ up-regulation is associated with poor survival in breast cancer, perturbs DNA replication and promotes genetic instability. European Journal of Cancer Supplements. 8(5). 35–35. 2 indexed citations
9.
Hurvitz, Sara A., John Crown, John Forbes, et al.. (2009). CIRG/TORI 010: 10-Month Analysis of a Randomized Phase II Trial of Motesanib Plus Weekly Paclitaxel as First Line Therapy in HER2-Negative Metastatic Breast Cancer (MBC).. Cancer Research. 69(24_Supplement). 47–47. 5 indexed citations
10.
11.
Finn, RS, Carmelo Bengala, Justin Fairchild, et al.. (2009). Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059.. Cancer Research. 69(2_Supplement). 3118–3118. 59 indexed citations
12.
Addis, Bruce & H. Roché. (2008). Problems in mesothelioma diagnosis. Histopathology. 54(1). 55–68. 50 indexed citations
13.
Puisset, Florent, J. Alexandre, Jean‐Marc Tréluyer, et al.. (2007). Clinical pharmacodynamic factors in docetaxel toxicity. British Journal of Cancer. 97(3). 290–296. 29 indexed citations
14.
Jacquemier, Jocelyne, Frédérique Penault‐Llorca, Héla Mnif, et al.. (2006). Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue-microarrays (TMA). Journal of Clinical Oncology. 24(18_suppl). 509–509. 21 indexed citations
15.
Carpenter, J., H. Roché, Mario Campone, et al.. (2005). Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Journal of Clinical Oncology. 23(16_suppl). 564–564. 81 indexed citations
16.
Couteau, C., Florence Dalenc, Gwénaël Ferron, et al.. (2004). Neoadjuvant sequential treatment in women with breast cancer: FEC100 then docetaxel: Results in clinical practice. Journal of Clinical Oncology. 22(14_suppl). 749–749. 3 indexed citations
17.
Delord, Jean‐Pierre, et al.. (2003). [Primary dural lymphoma: a report of two cases with review of the literature].. PubMed. 159(6-7 Pt 1). 652–8. 22 indexed citations
18.
Roché, H. & Amaryll Perlesz. (2000). A Legitimate Choice and Voice: The Experience of Adult Adoptees Who have Chosen Not to Search for their Biological Families. Adoption & Fostering. 24(2). 8–19. 4 indexed citations
19.
Chevallier, B, Alain Monnier, R Metz, et al.. (1990). Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast Cancer. American Journal of Clinical Oncology. 13(5). 436–439. 19 indexed citations
20.
Bonneterre, Jacques, L. Mauriac, B. Weber, et al.. (1988). Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: Results of a double blind multicentre clinical trial. European Journal of Cancer and Clinical Oncology. 24(12). 1851–1853. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Mallery Breakdown of academic impact, for papers by Amy Krie Breakdown of academic impact, for papers by Paul T. Adams Breakdown of academic impact, for papers by Angela Sciandivasci Breakdown of academic impact, for papers by Nancy G. Iskander Breakdown of academic impact, for papers by Mohamed A. Gouda Breakdown of academic impact, for papers by Pam K. Mangat Breakdown of academic impact, for papers by Roman Groisberg Breakdown of academic impact, for papers by Edna Chow‐Maneval Breakdown of academic impact, for papers by Hielke J. Meulenbeld
Rankless by CCL
2026